Phase 1 Study of Sunitinib (SU011248) in Combination With Pemetrexed in Patients With Advanced Solid Malignancies in Japan.

Trial Profile

Phase 1 Study of Sunitinib (SU011248) in Combination With Pemetrexed in Patients With Advanced Solid Malignancies in Japan.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Sunitinib (Primary) ; Pemetrexed
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Dec 2009 Actual patient number (12) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2009 Interim results were reported at the 13th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top